BioCentury
ARTICLE | Company News

Biomira restructures

November 28, 2001 8:00 AM UTC

Biomira (BIOM; TSE: BRA) said it plans to suspend development of its Phase I autologous vaccine and its liposomal interleukin-2, which is in Phase II testing. As a result, the company will lay off 22 ...